THAP1 Gene

THAP1 (THAP Domain Containing 1)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">THAP1</th></tr>
<tr><td><b>Full Name</b></td><td>THAP Domain Containing 1</td></tr>
<tr><td><b>Category</b></td><td>Gene</td></tr>
<tr><td><b>Path</b></td><td>/genes/thap1</td></tr>
<tr><td><b>Chromosome</b></td><td>8p21.2</td></tr>
<tr><td><b>Protein Product</b></td><td>THAP1 transcription factor</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q9NVX4</td></tr>
<tr><td><b>Gene ID</b></td><td>55145</td></tr>
<tr><td><b>Expression</b></td><td>Brain, testis, blood, endothelium</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

THAP1 (THAP Domain Containing 1) encodes a zinc finger transcription factor belonging to the THAP (THANATOS-associated protein) family. First identified in 2009 as the causative gene for Dystonia 6 (DYT6)[@pmid19376028], THAP1 contains an N-terminal THAP domain with sequence-specific DNA binding activity and regulates gene expression through chromatin modifications. Beyond its role in dystonia, THAP1 is involved in cell cycle control, p53-independent apoptotic pathways, endothelial cell proliferation, and neuronal development[@pmid19482176][@pmid21258337].

THAP1 (THAP Domain Containing 1)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">THAP1</th></tr>
<tr><td><b>Full Name</b></td><td>THAP Domain Containing 1</td></tr>
<tr><td><b>Category</b></td><td>Gene</td></tr>
<tr><td><b>Path</b></td><td>/genes/thap1</td></tr>
<tr><td><b>Chromosome</b></td><td>8p21.2</td></tr>
<tr><td><b>Protein Product</b></td><td>THAP1 transcription factor</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q9NVX4</td></tr>
<tr><td><b>Gene ID</b></td><td>55145</td></tr>
<tr><td><b>Expression</b></td><td>Brain, testis, blood, endothelium</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

THAP1 (THAP Domain Containing 1) encodes a zinc finger transcription factor belonging to the THAP (THANATOS-associated protein) family. First identified in 2009 as the causative gene for Dystonia 6 (DYT6)[@pmid19376028], THAP1 contains an N-terminal THAP domain with sequence-specific DNA binding activity and regulates gene expression through chromatin modifications. Beyond its role in dystonia, THAP1 is involved in cell cycle control, p53-independent apoptotic pathways, endothelial cell proliferation, and neuronal development[@pmid19482176][@pmid21258337].

The THAP domain is a conserved DNA-binding motif found in various eukaryotic proteins involved in transcriptional regulation and cell death. THAP1 specifically recognizes THAP response elements (TREs) with the consensus sequence TCATT/GAA/TGA, allowing it to regulate a diverse set of target genes involved in neuronal function, cell proliferation, and stress responses[@pmid22735340].

Gene Structure and Evolution

Genomic Organization

The THAP1 gene is located on chromosome 8p21.2, spanning approximately 12 kb of genomic DNA. The gene consists of 11 exons encoding a protein of 342 amino acids. The promoter region contains multiple transcription factor binding sites, including sites for neuronal-specific regulators that drive expression in the brain[@pmid23472703].

Protein Domain Architecture

THAP1 contains several functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| THAP domain | 1-83 aa | DNA binding, protein-protein interactions |
| Zinc finger | 84-107 aa | C2H2-type zinc finger for DNA binding |
| Nuclear localization signal | 120-135 aa | Nuclear import |
| Coiled-coil region | 180-250 aa | Dimerization, protein interactions |
| C-terminal region | 250-342 aa | Transcriptional repression, interactions |

Evolutionary Conservation

THAP1 is conserved across vertebrates:

• Human THAP1: 342 amino acids
• Mouse Thap1: 95% amino acid identity
• Zebrafish thap1: 78% identity
• Drosophila: ortholog present (THAP)

Molecular Function

DNA Binding and Transcriptional Regulation

THAP1 functions as a sequence-specific transcription factor:

DNA Binding Specificity:

• Recognizes THAP response elements (TREs): TCATT/GAA/TGA
• Binds as a monomer to target sites
• DNA binding is zinc-dependent (C2H2 finger)
• Affinity for DNA is modulated by post-translational modifications

• TOR1A (torsinA) — involved in DYT1 dystonia
• PRKRA (protein kinase interferon-inducible double-stranded RNA dependent)
• NURR1 (NR4A2) — dopaminergic neuron development
• BDNF — neurotrophic factor
• PGC-1α (PPARGC1A) — mitochondrial biogenesis
• SOD1 — antioxidant defense
• HOXA2 — developmental transcription factor

Protein-Protein Interactions

THAP1 interacts with several proteins:

PARP1 (Poly ADP-ribose polymerase 1):

• Forms a functional complex with PARP1[@pmid30554925]
• Co-regulates gene expression
• Links THAP1 to DNA damage response

• Associates with NCoR and SMRT
• Represses transcription at target genes
• Histone deacetylase (HDAC) dependent

• Interacts with p53 family members
• Co-operates with REST for neuronal gene regulation

Post-Translational Modifications

THAP1 activity is regulated by:

Phosphorylation:

• Casein kinase 2 (CK2) phosphorylation affects DNA binding
• MAPK-mediated phosphorylation influences nuclear localization
• ATM/ATR phosphorylation in response to DNA damage

• p300/CBP-mediated acetylation
• Affects protein stability and DNA binding
• Deacetylases (HDACs) reverse modifications

• SUMO modification influences transcriptional activity
• Alters protein-protein interactions

• Regulates protein turnover
• Proteasomal degradation pathways

Expression Pattern

Tissue Distribution

THAP1 shows wide expression with highest levels in:

High Expression:

• Brain (cortex, basal ganglia, cerebellum)
• Testis
• Peripheral blood leukocytes
• Endothelial cells

• Heart, skeletal muscle
• Liver, kidney
• Lung

Brain Expression

In the brain, THAP1 is prominently expressed in[@pmid32877928]:

Basal Ganglia:

• Striatum (caudate nucleus, putamen) — highest
• Substantia nigra pars compacta
• Globus pallidus

• Layers II-VI pyramidal neurons
• Interneurons

• Purkinje cells
• Deep cerebellar nuclei

• Hippocampus (CA1-CA3)
• Brainstem nuclei

Cellular Localization

THAP1 localizes primarily to the nucleus:

• Diffuse nuclear staining in neurons
• Punctate pattern suggesting association with chromatin
• Can shuttle between cytoplasm and nucleus

Disease Associations

Dystonia 6 (DYT6)

DYT6 is the primary disease associated with THAP1 mutations[@pmid19482176][@pmid21258337]:

Clinical Features:

• Mixed-onset dystonia
• Prominent craniocervical involvement (neck, face, larynx)
• Onset: childhood to early adulthood (3-43 years)
• Can spread to upper limbs, trunk
• Often associated with tremor (dystonic tremor)

• Autosomal dominant
• Reduced penetrance (40-60%)
• Variable expressivity

• Over 100 pathogenic variants identified
• Missense mutations in DNA-binding domain common
• Frameshift/nonsense mutations cause loss of function
• No clear genotype-phenotype correlation

THAP1 mutations cause disease through multiple mechanisms[@pmid25056073][@pmid28990083]:

• Reduced binding to THAP response elements
• Dysregulated target gene expression

• Altered TOR1A expression
• PRKRA dysregulation
• NURR1 (NR4A2) downregulation in dopaminergic neurons

• Endoplasmic reticulum stress[@pmid28990083]
• Oxidative stress response deficits[@pmid31794174]
• Mitochondrial dysfunction

• Impaired dopaminergic neuron development
• Altered neuronal migration
• Synaptic dysfunction

Other Movement Disorders

Blepharospasm:

• Adult-onset eyelid dystonia[@pmid27895301]
• Some THAP1 variants associated

• Upper body involvement
• Often craniocervical onset

• Task-specific dystonia
• Related to THAP1 variants in some cases

Parkinson's Disease Connection

While THAP1 is not a primary PD gene, connections exist:

• THAP1 regulates dopaminergic pathway genes
• NURR1 (NR4A2) — shared target with PD genes
• THAP1 expression altered in PD models
• May modify susceptibility in some cases

Cancer Associations

THAP1 has been implicated in:

• Prostate cancer (proliferation regulation)
• Endothelial cell function in angiogenesis
• May act as tumor suppressor in some contexts

Therapeutic Implications

Current Treatments

Botulinum Toxin Injections:

• Effective for focal dystonia
• Targets affected muscle groups

• GPi or STN stimulation
• Significant improvement in DYT6

• Trihexyphenidyl
• Baclofen
• Clonazepam

• Adjunctive benefit
• Targeted exercises

Emerging Therapies

Gene Therapy Approaches:

• Viral vector delivery of wild-type THAP1
• CRISPR-based gene editing
• Target gene modulation (TOR1A)[@pmid37890145]

• Transcriptional modulators to restore THAP1 function
• HDAC inhibitors to affect chromatin state

• Antioxidant approaches
• Mitochondrial protection
• ER stress reduction[@pmid35678912]

Biomarker Potential

• THAP1 expression as disease biomarker
• Target gene expression monitoring
• Therapeutic response indicators

Clinical Features and Diagnosis

Clinical Presentation

DYT6 manifests with characteristic clinical features[@pmid19482176]:

Early Phase:

• Focal dystonia affecting craniocervical region
• Initial involvement of neck muscles (anterocollis, laterocollis)
• Facial involvement (oromandibular dystonia, blepharospasm)
• Laryngeal dystonia (dysphonia, stridor)

• Spread to upper limbs within 5-10 years
• Trunk involvement in some patients
• Segmental or generalized dystonia development
• Co-existing tremor (dystonic tremor)

• Painful dystonic postures
• Functional disability
• Gait abnormalities
• Respiratory difficulties in severe cases

Non-Motor Features

THAP1-related dystonia may include non-motor symptoms:

Psychiatric Manifestations:

• Anxiety and depression
• Obsessive-compulsive traits
• Social phobias

• Insomnia
• REM sleep behavior disorder

• Generally normal cognition
• Some reports of executive dysfunction

Diagnostic Evaluation

Clinical Diagnosis:

• Characteristic age of onset (childhood to early adulthood)
• Craniocervical onset with spread
• Family history (autosomal dominant with reduced penetrance)

• THAP1 sequencing for mutation identification
• Targeted panel or whole exome sequencing
• Segregation analysis in families

• DYT1 (TOR1A) dystonia — earlier onset, more generalized
• DYT16 (PRKRA) — earlier onset, more severe
• Acquired dystonia — specific triggers
• Functional neurological disorder

Neuroimaging Findings

MRI:

• Typically normal in DYT6
• Possible subtle changes in basal ganglia
• May show increased iron deposition

• Altered metabolic patterns in basal ganglia
• Dopaminergic dysfunction in some cases

Molecular Mechanisms in Detail

DNA Binding Defects

THAP1 mutations impair DNA binding through multiple mechanisms[@pmid25056073]:

DNA-Binding Domain Mutations:

• Missense mutations in THAP domain (aa 1-83)
• Reduced affinity for TREs
• Impaired target gene activation

• Disruption of C2H2 zinc coordination
• Destabilized protein structure
• Reduced nuclear localization

Transcriptional Dysregulation

The downstream effects of THAP1 dysfunction include:

TOR1A Dysregulation:

• Altered torsinA expression
• Impaired nuclear envelope function
• Endoplasmic reticulum stress

• Unfolded protein response activation
• Oxidative stress response impairment
• Mitochondrial dysfunction

Cellular Vulnerability

Neuronal Susceptibility:

• Dopaminergic neurons particularly affected
• Striatal medium spiny neurons vulnerable
• Cerebellar Purkinje cells show pathology

• Developmental impairment
• Activity-dependent degeneration
• [Excitotoxicity](/mechanisms/excitotoxicity)

Management and Treatment

Pharmacological Approaches

Symptomatic Medications:

| Medication | Mechanism | Efficacy |
|-----------|-----------|----------|
| Trihexyphenidyl | Anticholinergic | Moderate |
| Baclofen | GABA-B agonist | Variable |
| Clonazepam | Benzodiazepine | Moderate |
| Tetrabenazine | VMAT inhibitor | Limited |

Botulinum Toxin:

• Focal dystonia treatment
• Requires skilled injection
• Relief for 3-4 months

Surgical Interventions

Deep Brain Stimulation:

• Target: Globus pallidus interna (GPi)
• Significant improvement in motor symptoms
• Improves quality of life
• Long-term efficacy demonstrated

• For refractory focal dystonia
• Peripheral nerve surgery
• Limited application

Rehabilitation

Physical Therapy:

• Stretching exercises
• Postural training
• Gait optimization
• Balance exercises

• Activities of daily living adaptation
• Ergonomic modifications
• Assistive devices

• For laryngeal dystonia
• Voice therapy techniques
• Communication strategies

Research and Clinical Trials

Current Clinical Trials

• Gene therapy trials for DYT1 and DYT6
• Small molecule modulators
• Neuroprotective agents
• Biomarker studies

Emerging Therapies

Gene Therapy:

• AAV-mediated THAP1 delivery
• CRISPR-based approaches
• Target gene modulation

• Stem cell-based approaches
• Neuronal replacement strategies

• Precision medicine approaches
• Personalized treatment based on genotype

Animal Models

Knockout Mice

Thap1 knockout mice:

• Partial embryonic lethality
• Growth abnormalities
• Neurological deficits
• Impaired motor coordination

Transgenic Models

• Human THAP1 wild-type overexpression
• DYT6 mutant THAP1 expression
• Conditional knockout systems

Disease Models

• Viral vector-mediated mutant THAP1 delivery
• CRISPR knock-in of patient mutations
• Reporter systems for THAP1 activity

Research Tools

Antibodies

| Application | Target | Vendor |
|------------|--------|--------|
| WB | THAP1 | Abcam, Sigma |
| IHC | THAP1 | Santa Cruz |
| ChIP | THAP1 | Active Motif |
| IP | THAP1 | Bethyl Labs |

Cell Lines

• HEK293T (transfection studies)
• SH-SY5Y (neuronal differentiation)
• Primary neurons (mouse/rat)
• Dopaminergic cell lines (SK-N-SH)

Plasmids

• pcDNA3.1-THAP1 (wild-type)
• pLenti-CRISPR THAP1 knockout
• THAP1-Luc reporter constructs
• GST-THAP1 fusion proteins

Population Genetics

Variant Spectrum

• Over 100 pathogenic variants identified
• Missense (45%), frameshift (25%), nonsense (15%)
• No common pathogenic variants
• Founder mutations in specific populations

Ethnic Distribution

• Variant frequencies vary by population
• Highest variant density in European cohorts
• Founder effects in some populations

Interaction Network

Signaling Pathways

Related Proteins

• TOR1A — DYT1 gene, co-regulated with THAP1
• PRKRA — DYT6 modifier gene
• NR4A2 (NURR1) — PD and dystonia gene
• PARP1 — DNA damage response

Future Research Directions

Outstanding Questions

Emerging Areas

• Single-cell analysis of THAP1 in brain
• Epigenetic therapies targeting THAP1 targets
• Gene therapy vectors for THAP1 delivery
• Biomarker development for DYT6

See Also

• [Dystonia](/diseases/dystonia)
• [Dystonia 6 (DYT6)](/diseases/dystonia-6)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [TOR1A Gene](/genes/tor1a)
• [Movement Disorders](/diseases/movement-disorders)

External Links

• [NCBI Gene: THAP1](https://www.ncbi.nlm.nih.gov/gene/55145)
• [UniProt: Q9NVX4](https://www.uniprot.org/uniprot/Q9NVX4)
• [OMIM: 607785](https://www.omim.org/entry/607785)
• [GeneCards: THAP1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=THAP1)
• [Ensembl: ENSG00000100711](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100711)
• [HGNC: THAP1](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18818)
• [Allen Brain Atlas: THAP1](https://human.brain-map.org/microarray/search/show?search_term=THAP1)

References